Ann: Application for quotation of securities - DXB, page-115

Yeah I agree. And if the contribution from Irbesartan is in the order of 18% then DMX-200 only has to reduce the PCR by 22% on top of baseline to achieve FPRE (40% reduction in total). When you look at the results from all DMX-200 trials this looks like a reasonable threshold to meet.

I'd still like to know more about how this will translate to eGFR slope results. A lot of the past trials have included a requirement to monitor eGFR in patients, but not necessarily report it as part of the trial or as an endpoint. So I'm wondering if Dimerix do in fact have some evidence of meaningful eGFR slope reduction in patients which showed significant PCR reduction which hasn't been disclosed publicly.